Dr. Michelle Scott -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Michelle Scott, a Gastroenterology physician based in City, SC. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Michelle Scott has received $832.38 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Michelle Scott has received a total of $832.38 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $832.38 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Michelle Scott's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription

The largest payment category for Dr. Michelle Scott is Speaking & Education, accounting for 0% ($0.00) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Michelle Scott. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Allergan (AbbVie)$832.381

Dr. Michelle Scott has a financial relationship with Allergan (AbbVie), receiving $832.38 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Michelle Scott's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Michelle Scott has received $832.38 across 1 pharmaceutical payments as a Gastroenterology physician in City, SC. Top paying companies include Allergan (AbbVie) ($832.38). Dr. Scott received a single payment of $832 in 2025, indicating a limited engagement with pharmaceutical companies. The entire payment originated from Allergan (AbbVie), suggesting a focused relationship with this specific manufacturer. The payment was categorized as 'general', providing no specific details on the nature of the interaction.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Michelle Scott is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may want to inquire about the nature of any payments their doctor receives from pharmaceutical companies to understand potential influences on treatment recommendations. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Michelle Scott Compares to Other Gastroenterology Physicians

As a Gastroenterologist, Dr. Scott's payment profile is less common, as many specialists in this field have more extensive interactions with pharmaceutical companies.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Michelle Scott in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Allergan (AbbVie)$832.38generalN/A2025-08-07Not Assessed

Frequently Asked Questions About Dr. Michelle Scott's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Michelle Scott received?

Michelle Scott has received a total of $832.38 across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Michelle Scott taking too much pharma money?

Michelle Scott has received $832.38 in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Gastroenterology), the types of payments, and how they compare to peers. The largest payment category is general ($832.38). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Michelle Scott?

The top pharmaceutical companies paying Michelle Scott are: Allergan (AbbVie) ($832.38). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Michelle Scott receive?

Michelle Scott's payments by type: general: $832.38.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Michelle Scott's payments compare to other Gastroenterology doctors?

To compare, look at the total amount ($832.38), number of payments (1), and the types of payments received. Gastroenterology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Michelle Scott's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1984843191). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Michelle Scott's pharma payment profile?

The doctor has only one recorded payment, making it difficult to establish a comprehensive payment profile. Michelle Scott has received $832.38 in total pharma payments.

How does Michelle Scott compare to peers in Gastroenterology?

As a Gastroenterologist, Dr. Scott's payment profile is less common, as many specialists in this field have more extensive interactions with pharmaceutical companies.

Are Michelle Scott's pharma relationships typical for Gastroenterology?

The payment represents 100% of the total amount received from a single company, highlighting a lack of diversification in pharmaceutical relationships.

What should patients of Michelle Scott know about these payments?

Patients may want to inquire about the nature of any payments their doctor receives from pharmaceutical companies to understand potential influences on treatment recommendations.

What patterns are visible in Michelle Scott's payment history?

The 'general' payment type offers minimal insight into the specific services or activities that led to the compensation.

Understanding This Doctor Payment Report

This transparency report for Dr. Michelle Scott is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Michelle Scott's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Michelle Scott and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.